Ivo Mueller

List of Publications by Year
in descending order

370	16,071	18482 62	34986 98
papers	citations	h-index	g-index

404	404	404	10762
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infectious Diseases, The, 2009, 9, 555-566.	9.1	565
2	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	27.8	450
3	A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010. PLoS Neglected Tropical Diseases, 2012, 6, e1814.	3.0	448
4	Genome-wide and fine-resolution association analysis of malaria in West Africa. Nature Genetics, 2009, 41, 657-665.	21.4	345
5	Ultra-Sensitive Detection of Plasmodium falciparum by Amplification of Multi-Copy Subtelomeric Targets. PLoS Medicine, 2015, 12, e1001788.	8.4	276
6	Plasmodium malariae and Plasmodium ovale â€“ the â€˜bashfulâ€™ malaria parasites. Trends in Parasitology, 2007, 23, 278-283.	3.3	235
7	Immunoglobulin G Subclass-Specific Responses against <i>Plasmodium falciparum</i> Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness. Infection and Immunity, 2009, 77, 1165-1174.	2.2	235
8	Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model. PLoS Medicine, 2015, 12, e1001891.	8.4	217
9	Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to <i>Plasmodium falciparum</i> Malaria for Vaccine and Biomarker Development. Journal of Immunology, 2013, 191, 795-809.	0.8	213
10	Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax. Nature Genetics, 2016, 48, 953-958.	21.4	194
11	Reported reasons for not using a mosquito net when one is available: a review of the published literature. Malaria Journal, 2011, 10, 83.	2.3	187
12	Strategies for Detection of Plasmodium species Gametocytes. PLoS ONE, 2013, 8, e76316.	2.5	185
13	Association between Naturally Acquired Antibodies to Erythrocyteâ€Binding Antigens of<i>Plasmodium falciparum</i>and Protection from Malaria and Highâ€Density Parasitemia. Clinical Infectious Diseases, 2010, 51, e50-e60.	5.8	184
14	A Trial of Combination Antimalarial Therapies in Children from Papua New Guinea. New England Journal of Medicine, 2008, 359, 2545-2557.	27.0	174
15	Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nature Genetics, 2016, 48, 959-964.	21.4	169
16	THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN. American Journal of Tropical Medicine and Hygiene, 2007, 76, 997-1008.	1.4	149
17	Association of Early Interferonâ€Î³ Production with Immunity to Clinical Malaria: A Longitudinal Study among Papua New Guinean Children. Clinical Infectious Diseases, 2008, 47, 1380-1387.	5.8	148
18	Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage <i>Plasmodium vivax</i> infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8363-8368.	7.1	147

#	Article	IF	Citations
19	Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nature Communications, 2018, 9, 2223.	12.8	142
20	Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malaria Journal, 2010, 9, 361.	2.3	126
21	Differential Patterns of Infection and Disease with P. falciparum and P. vivax in Young Papua New Guinean Children. PLoS ONE, 2010, 5, e9047.	2.5	124
22	Acquisition of Antibodies against Plasmodium falciparum Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response. Infection and Immunity, 2015, 83, 646-660.	2.2	121
23	The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density. Nature Communications, 2019, 10, 1433.	12.8	121
24	Geographical Structure of Diversity and Differences between Symptomatic and Asymptomatic Infections for Plasmodium falciparum Vaccine Candidate AMA1. Infection and Immunity, 2003, 71, 1416-1426.	2.2	118
25	Relapses Contribute Significantly to the Risk of Plasmodium vivax Infection and Disease in Papua New Guinean Children 1â€“5 Years of Age. Journal of Infectious Diseases, 2012, 206, 1771-1780.	4.0	108
26	Force of infection is key to understanding the epidemiology of <i>Plasmodium falciparum</i> malaria in Papua New Guinean children. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10030-10035.	7.1	106
27	The risk of malarial infections and disease in Papua New Guinean children. American Journal of Tropical Medicine and Hygiene, 2007, 76, 997-1008.	1.4	106
28	Clinical Immunity to Malaria. Current Molecular Medicine, 2006, 6, 205-221.	1.3	100
29	Evaluation of<i>Plasmodium vivax</i>Genotyping Markers for Molecular Monitoring in Clinical Trials. Journal of Infectious Diseases, 2009, 199, 1074-1080.	4.0	97
30	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
31	Blood-Stage Parasitaemia and Age Determine Plasmodium falciparum and P. vivax Gametocytaemia in Papua New Guinea. PLoS ONE, 2015, 10, e0126747.	2.5	94
32	Sensitive and accurate quantification of human malaria parasites using droplet digital PCR (ddPCR). Scientific Reports, 2016, 6, 39183.	3.3	90
33	Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nature Medicine, 2020, 26, 741-749.	30.7	90
34	Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. ELife, 2014, 3, .	6.0	88
35	Development of vaccines for Plasmodium vivax malaria. Vaccine, 2015, 33, 7489-7495.	3.8	86
36	Development of amplicon deep sequencing markers and data analysis pipeline for genotyping multi-clonal malaria infections. BMC Genomics, 2017, 18, 864.	2.8	86

#	Article	IF	Citations
37	Identity-by-descent analyses for measuring population dynamics and selection in recombining pathogens. PLoS Genetics, 2018, 14, e1007279.	3.5	86
38	Cellular Tumor Necrosis Factor, Gamma Interferon, and Interleukin-6 Responses as Correlates of Immunity and Risk of Clinical <i>Plasmodium falciparum</i> Malaria in Children from Papua New Guinea. Infection and Immunity, 2009, 77, 3033-3043.	2.2	84
39	Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous <i>Plasmodium vivax</i> Strains in Papua New Guinean Children. Infection and Immunity, 2009, 77, 4009-4017.	2.2	84
40	Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against <i>Plasmodium falciparum</i> Malaria. Journal of Immunology, 2010, 185, 6157-6167.	0.8	84
41	Natural Acquisition of Immunity to Plasmodium vivax. Advances in Parasitology, 2013, 81, 77-131.	3.2	84
42	Clinical and laboratory predictors of imported malaria in an outpatient setting: an aid to medical decision making in returning travelers with fever.. American Journal of Tropical Medicine and Hygiene, 2002, 66, 481-486.	1.4	83
43	High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malaria Journal, 2009, 8, 41.	2.3	82
44	High Rates of Asymptomatic, Sub-microscopic Plasmodium vivax Infection and Disappearing Plasmodium falciparum Malaria in an Area of Low Transmission in Solomon Islands. PLoS Neglected Tropical Diseases, 2015, 9, e0003758.	3.0	82
45	Opsonising Antibodies to P. falciparum Merozoites Associated with Immunity to Clinical Malaria. PLoS ONE, 2013, 8, e74627.	2.5	82
46	Assessment of ultra-sensitive malaria diagnosis versus standard molecular diagnostics for malaria elimination: an in-depth molecular community cross-sectional study. Lancet Infectious Diseases, The, 2018, 18, 1108-1116.	9.1	81
47	Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathogens, 2020, 16, e1009133.	4.7	81
48	Pharmacokinetics and Efficacy of Piperaquine and Chloroquine in Melanesian Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2008, 52, 237-243.	3.2	80
49	Malaria Molecular Epidemiology: Lessons from the International Centers of Excellence for Malaria Research Network. American Journal of Tropical Medicine and Hygiene, 2015, 93, 79-86.	1.4	80
50	Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission. Malaria Journal, 2010, 9, 336.	2.3	79
51	Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Medicine, 2018, 16, 61.	5.5	79
52	Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe, The, 2021, 2, e60-e69.	7.3	78
53	Infectivity of symptomatic and asymptomatic Plasmodium vivax infections to a Southeast Asian vector, Anopheles dirus. International Journal for Parasitology, 2017, 47, 163-170.	3.1	76
54	Targets of complement-fixing antibodies in protective immunity against malaria in children. Nature Communications, 2019, 10, 610.	12.8	76

#	Article	IF	Citations
55	Placental Malaria-Associated Inflammation Disturbs the Insulin-like Growth Factor Axis of Fetal Growth Regulation. Journal of Infectious Diseases, 2011, 203, 561-569.	4.0	75
56	Features and Prognosis of Severe Malaria Caused by Plasmodium falciparum, Plasmodium vivax and Mixed Plasmodium Species in Papua New Guinean Children. PLoS ONE, 2011, 6, e29203.	2.5	74
57	Ownership and usage of mosquito nets after four years of large-scale free distribution in Papua New Guinea. Malaria Journal, 2012, 11, 192.	2.3	74
58	Mosquito behaviour change after distribution of bednets results in decreased protection against malaria exposure. Journal of Infectious Diseases, 2017, 215, jiw615.	4.0	74
59	CHANGING PATTERNS OF PLASMODIUM BLOOD-STAGE INFECTIONS IN THE WOSERA REGION OF PAPUA NEW GUINEA MONITORED BY LIGHT MICROSCOPY AND HIGH THROUGHPUT PCR DIAGNOSIS. American Journal of Tropical Medicine and Hygiene, 2006, 75, 588-596.	1.4	74
60	Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malaria Journal, 2009, 8, 250.	2.3	73
61	Multiplicity and Diversity of Plasmodium vivax Infections in a Highly Endemic Region in Papua New Guinea. PLoS Neglected Tropical Diseases, 2011, 5, e1424.	3.0	73
62	Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial. BMC Medicine, 2015, 13, 9.	5.5	73
63	The Biology of <i>Plasmodium vivax</i>. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a025585.	6.2	72
64	Rise in Malaria Incidence Rates in South Africa: A Small-Area Spatial Analysis of Variation in Time Trends. American Journal of Epidemiology, 2002, 155, 257-264.	3.4	69
65	Pharmacokinetics of Chloroquine and Monodesethylchloroquine in Pregnancy. Antimicrobial Agents and Chemotherapy, 2010, 54, 1186-1192.	3.2	66
66	Reduced Plasmodium vivax Erythrocyte Infection in PNG Duffy-Negative Heterozygotes. PLoS ONE, 2007, 2, e336.	2.5	65
67	Î³Î´ T cells and CD14+ Monocytes Are Predominant Cellular Sources of Cytokines and Chemokines Associated With Severe Malaria. Journal of Infectious Diseases, 2014, 210, 295-305.	4.0	65
68	Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria. PLoS ONE, 2012, 7, e51023.	2.5	65
69	Factors Affecting Attendance at and Timing of Formal Antenatal Care: Results from a Qualitative Study in Madang, Papua New Guinea. PLoS ONE, 2014, 9, e93025.	2.5	64
70	Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia. ELife, 2017, 6, .	6.0	64
71	Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development. ELife, 2017, 6, .	6.0	64
72	Population Genetic Analysis of Plasmodium falciparum Parasites Using a Customized Illumina GoldenGate Genotyping Assay. PLoS ONE, 2011, 6, e20251.	2.5	63

#	Article	IF	Citations
73	Plasmodium vivax Populations Are More Genetically Diverse and Less Structured than Sympatric Plasmodium falciparum Populations. PLoS Neglected Tropical Diseases, 2015, 9, e0003634.	3.0	62
74	Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. Malaria Journal, 2010, 9, 29.	2.3	61
75	Implications of <i>Plasmodium vivax</i> Biology for Control, Elimination, and Research. American Journal of Tropical Medicine and Hygiene, 2016, 95, 4-14.	1.4	60
76	Plasmodium vivax Diversity and Population Structure across Four Continents. PLoS Neglected Tropical Diseases, 2015, 9, e0003872.	3.0	59
77	The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Scientific Reports, 2016, 6, 33094.	3.3	59
78	Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax. Nature Communications, 2018, 9, 3300.	12.8	59
79	Evaluation of CDC light traps for mosquito surveillance in a malaria endemic area on the Thai-Myanmar border. Parasites and Vectors, 2015, 8, 636.	2.5	58
80	Variation in relapse frequency and the transmission potential of <i>Plasmodium vivax</i> malaria. Proceedings of the Royal Society B: Biological Sciences, 2016, 283, 20160048.	2.6	58
81	Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. American Journal of Tropical Medicine and Hygiene, 2006, 75, 588-96.	1.4	58
82	Insights into the naturally acquired immune response to<i>Plasmodium vivax</i>malaria. Parasitology, 2016, 143, 154-170.	1.5	57
83	Plasmodium vivax Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children. PLoS Neglected Tropical Diseases, 2016, 10, e0005014.	3.0	56
84	High proportions of asymptomatic and submicroscopic Plasmodium vivax infections in a peri-urban area of low transmission in the Brazilian Amazon. Parasites and Vectors, 2018, 11, 194.	2.5	54
85	Pharmacokinetic Properties of Sulfadoxine-Pyrimethamine in Pregnant Women. Antimicrobial Agents and Chemotherapy, 2009, 53, 4368-4376.	3.2	53
86	Desbutyl-Lumefantrine Is a Metabolite of Lumefantrine with Potent <i>In Vitro</i> Antimalarial Activity That May Influence Artemether-Lumefantrine Treatment Outcome. Antimicrobial Agents and Chemotherapy, 2011, 55, 1194-1198.	3.2	53
87	Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study. PLoS Medicine, 2012, 9, e1001305.	8.4	53
88	A High Force of Plasmodium vivax Blood-Stage Infection Drives the Rapid Acquisition of Immunity in Papua New Guinean Children. PLoS Neglected Tropical Diseases, 2013, 7, e2403.	3.0	53
89	How Much Remains Undetected? Probability of Molecular Detection of Human Plasmodia in the Field. PLoS ONE, 2011, 6, e19010.	2.5	53
90	Effectiveness of dengue control practices in household water containers in Northeast Thailand. Tropical Medicine and International Health, 2005, 10, 755-763.	2.3	52

#	Article	IF	Citations
91	Uncovering the transmission dynamics of<i>Plasmodium vivax</i>using population genetics. Pathogens and Global Health, 2015, 109, 142-152.	2.3	52
92	Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions. PLoS Neglected Tropical Diseases, 2017, 11, e0005888.	3.0	52
93	Parvovirus B19 Infection Contributes to Severe Anemia in Young Children in Papua New Guinea. Journal of Infectious Diseases, 2006, 194, 146-153.	4.0	51
94	Evaluation of the Antigenic Diversity of Placenta-Binding <i>Plasmodium falciparum</i> Variants and the Antibody Repertoire among Pregnant Women. Infection and Immunity, 2010, 78, 1963-1978.	2.2	51
95	The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria. PLoS ONE, 2012, 7, e45253.	2.5	51
96	Very high carriage of gametocytes in asymptomatic low-density Plasmodium falciparum and P. vivax infections in western Thailand. Parasites and Vectors, 2017, 10, 512.	2.5	51
97	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
98	The population structure of Plasmodium falciparum and Plasmodium vivax during an epidemic of malaria in the Eastern Highlands of Papua New Guinea.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 459-464.	1.4	51
99	Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 5306-5313.	3.2	50
100	Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against Plasmodium falciparum in Humans. PLoS ONE, 2011, 6, e27705.	2.5	49
101	High Levels of Genetic Diversity of Plasmodium falciparum Populations in Papua New Guinea despite Variable Infection Prevalence. American Journal of Tropical Medicine and Hygiene, 2013, 88, 718-725.	1.4	49
102	Low Efficacy of Amodiaquine or Chloroquine Plus Sulfadoxine-Pyrimethamine against Plasmodium falciparum and P. vivax Malaria in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2007, 77, 947-954.	1.4	49
103	Enhanced detection of gametocytes by magnetic deposition microscopy predicts higher potential for Plasmodium falciparum transmission. Malaria Journal, 2008, 7, 66.	2.3	48
104	A Large Plasmodium vivax Reservoir and Little Population Structure in the South Pacific. PLoS ONE, 2013, 8, e66041.	2.5	48
105	Malaria Epidemiology at the Clone Level. Trends in Parasitology, 2017, 33, 974-985.	3.3	48
106	Global Population Structure of the Genes Encoding the Malaria Vaccine Candidate, Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1). PLoS Neglected Tropical Diseases, 2013, 7, e2506.	3.0	47
107	Rosetting in Plasmodium vivax: A Cytoadhesion Phenotype Associated with Anaemia. PLoS Neglected Tropical Diseases, 2013, 7, e2155.	3.0	47
108	Limited antigenic diversity of Plasmodium falciparumapical membrane antigen 1 supports the development of effective multi-allele vaccines. BMC Medicine, 2014, 12, 183.	5.5	47

#	Article	IF	Citations
109	Risk factors and pregnancy outcomes associated with placental malaria in a prospective cohort of Papua New Guinean women. Malaria Journal, 2017, 16, 427.	2.3	47
110	Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. PLoS Medicine, 2017, 14, e1002373.	8.4	46
111	Burden and impact of Plasmodium vivax in pregnancy: A multi-centre prospective observational study. PLoS Neglected Tropical Diseases, 2017, 11, e0005606.	3.0	46
112	Rectal Administration of Artemisinin Derivatives for the Treatment of Malaria. JAMA - Journal of the American Medical Association, 2007, 297, 2381.	7.4	45
113	Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 313-324.	1.8	45
114	Higher Complexity of Infection and Genetic Diversity of Plasmodium vivax Than Plasmodium falciparum across all Malaria Transmission Zones of Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0716.	1.4	45
115	Chronic Exposure to Malaria Is Associated with Inhibitory and Activation Markers on Atypical Memory B Cells and Marginal Zone-Like B Cells. Frontiers in Immunology, 2017, 8, 966.	4.8	45
116	Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers. British Journal of Clinical Pharmacology, 2008, 65, 674-679.	2.4	43
117	Pharmacokinetic Properties of Azithromycin in Pregnancy. Antimicrobial Agents and Chemotherapy, 2010, 54, 360-366.	3.2	43
118	Placental Infection With Plasmodium vivax: A Histopathological and Molecular Study. Journal of Infectious Diseases, 2012, 206, 1904-1910.	4.0	43
119	Naturally Acquired Immune Responses to P. vivax Merozoite Surface Protein 3Î± and Merozoite Surface Protein 9 Are Associated with Reduced Risk of P. vivax Malaria in Young Papua New Guinean Children. PLoS Neglected Tropical Diseases, 2013, 7, e2498.	3.0	43
120	Structurally conserved erythrocyte-binding domain in <i>Plasmodium</i> provides a versatile scaffold for alternate receptor engagement. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E191-200.	7.1	43
121	Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination. Gates Open Research, 2019, 3, 131.	1.1	43
122	Malaria transmission dynamics surrounding the first nationwide long-lasting insecticidal net distribution in Papua New Guinea. Malaria Journal, 2016, 15, 25.	2.3	42
123	Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand. Vaccine Journal, 2016, 23, 117-124.	3.1	42
124	Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria. Frontiers in Microbiology, 2014, 5, 314.	3.5	41
125	Mitochondrial DNA from the eradicated European <i>Plasmodium vivax</i> and <i>P. falciparum</i> from 70-year-old slides from the Ebro Delta in Spain. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11495-11500.	7.1	41
126	Synergistic effect of IL-12 and IL-18 induces TIM3 regulation of Î³Î´ T cell function and decreases the risk of clinical malaria in children living in Papua New Guinea. BMC Medicine, 2017, 15, 114.	5.5	41

#	Article	IF	Citations
127	Imported Plasmodium falciparum and locally transmitted Plasmodium vivax: cross-border malaria transmission scenario in northwestern Thailand. Malaria Journal, 2017, 16, 258.	2.3	41
128	Sustained Malaria Control Over an 8-Year Period in Papua New Guinea: The Challenge of Low-Density Asymptomatic Plasmodium Infections. Journal of Infectious Diseases, 2017, 216, 1434-1443.	4.0	41
129	Severe Anemia in Papua New Guinean Children from a Malaria-Endemic Area: A Case-Control Etiologic Study. PLoS Neglected Tropical Diseases, 2012, 6, e1972.	3.0	40
130	Plasmodium vivax molecular diagnostics in community surveys: pitfalls and solutions. Malaria Journal, 2018, 17, 55.	2.3	40
131	Protective Immunity against Severe Malaria in Children Is Associated with a Limited Repertoire of Antibodies to Conserved PfEMP1 Variants. Cell Host and Microbe, 2019, 26, 579-590.e5.	11.0	40
132	An Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection. PLoS Neglected Tropical Diseases, 2016, 10, e0004639.	3.0	40
133	Prevalence of malaria across Papua New Guinea after initial rollâ€out of insecticideâ€treated mosquito nets. Tropical Medicine and International Health, 2015, 20, 1745-1755.	2.3	39
134	Phylogeography of <i>var</i> gene repertoires reveals fineâ€scale geospatial clustering of <i>Plasmodium falciparum</i> populations in a highly endemic area. Molecular Ecology, 2015, 24, 484-497.	3.9	39
135	Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. Infection and Immunity, 2016, 84, 2175-2184.	2.2	39
136	Key Knowledge Gaps for <i>Plasmodium vivax</i> Control and Elimination. American Journal of Tropical Medicine and Hygiene, 2016, 95, 62-71.	1.4	39
137	Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial. PLoS Medicine, 2012, 9, e1001195.	8.4	38
138	Highly heterogeneous residual malaria risk in western Thailand. International Journal for Parasitology, 2019, 49, 455-462.	3.1	38
139	Plasmodium vivax Malaria Viewed through the Lens of an Eradicated European Strain. Molecular Biology and Evolution, 2020, 37, 773-785.	8.9	38
140	Changes in malaria burden and transmission in sentinel sites after the roll-out of long-lasting insecticidal nets in Papua New Guinea. Parasites and Vectors, 2016, 9, 340.	2.5	37
141	Preterm or Not â€“ An Evaluation of Estimates of Gestational Age in a Cohort of Women from Rural Papua New Guinea. PLoS ONE, 2015, 10, e0124286.	2.5	37
142	Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Pharmacokinetic Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 2472-2484.	3.2	36
143	Predicting Antidisease Immunity Using Proteome Arrays and Sera from Children Naturally Exposed to Malaria. Molecular and Cellular Proteomics, 2014, 13, 2646-2660.	3.8	36
144	Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand. Malaria Journal, 2017, 16, 178.	2.3	36

#	Article	IF	Citations
145	Longitudinal tracking and quantification of individual Plasmodium falciparum clones in complex infections. Scientific Reports, 2019, 9, 3333.	3.3	36
146	A Multiplex Ligase Detection Reaction-Fluorescent Microsphere Assay for Simultaneous Detection of Single Nucleotide Polymorphisms Associated with Plasmodium falciparum Drug Resistance. Journal of Clinical Microbiology, 2007, 45, 752-761.	3.9	35
147	Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmission. Malaria Journal, 2014, 13, 233.	2.3	35
148	Plasmodium vivax and Plasmodium falciparum infection dynamics: re-infections, recrudescences and relapses. Malaria Journal, 2018, 17, 170.	2.3	35
149	EPIDEMIC MALARIA IN THE HIGHLANDS OF PAPUA NEW GUINEA. American Journal of Tropical Medicine and Hygiene, 2005, 72, 554-560.	1.4	35
150	Pregnancy and Malaria Exposure Are Associated with Changes in the B Cell Pool and in Plasma Eotaxin Levels. Journal of Immunology, 2014, 193, 2971-2983.	0.8	34
151	Malaria Epidemiology and Control Within the International Centers of Excellence for Malaria Research. American Journal of Tropical Medicine and Hygiene, 2015, 93, 5-15.	1.4	34
152	Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of <i>Plasmodium falciparum</i> into human erythrocytes. Cellular Microbiology, 2019, 21, e13030.	2.1	34
153	Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Tolerability, Safety, and Preliminary Efficacy Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 2465-2471.	3.2	33
154	Insecticide-treated nets and malaria prevalence, Papua New Guinea, 2008â€“2014. Bulletin of the World Health Organization, 2017, 95, 695-705B.	3.3	33
155	Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2007, 77, 947-54.	1.4	33
156	The Sensitivity of the OptiMAL Rapid Diagnostic Test to the Presence of Plasmodium falciparum Gametocytes Compromises Its Ability To Monitor Treatment Outcomes in an Area of Papua New Guinea in which Malaria Is Endemic. Journal of Clinical Microbiology, 2007, 45, 627-630.	3.9	32
157	Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. Journal of Infectious Diseases, 2021, 224, 1489-1499.	4.0	32
158	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
159	The complex relationship of exposure to new Plasmodium infections and incidence of clinical malaria in Papua New Guinea. ELife, 2017, 6, .	6.0	32
160	Rapid Diagnostic Testâ€“Based Management of Malaria: An Effectiveness Study in Papua New Guinean Infants With Plasmodium falciparum and Plasmodium vivax Malaria. Clinical Infectious Diseases, 2012, 54, 644-651.	5.8	31
161	Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial. PLoS Medicine, 2014, 11, e1001773.	8.4	31
162	Novel Genotyping Tools for Investigating Transmission Dynamics of Plasmodium falciparum. Journal of Infectious Diseases, 2014, 210, 1188-1197.	4.0	31

#	Article	IF	Citations
163	Human Immunization With a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains. Journal of Infectious Diseases, 2018, 218, 35-43.	4.0	31
164	Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity. Nature Communications, 2020, 11, 953.	12.8	31
165	Plasma Plasmodium falciparum Histidine-Rich Protein-2 Concentrations Do Not Reflect Severity of Malaria in Papua New Guinean Children. Clinical Infectious Diseases, 2011, 52, 440-446.	5.8	30
166	Progress in mosquito net coverage in Papua New Guinea. Malaria Journal, 2014, 13, 242.	2.3	30
167	Population Pharmacokinetics, Tolerability, and Safety of Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine-Piperaquine in Pregnant and Nonpregnant Papua New Guinean Women. Antimicrobial Agents and Chemotherapy, 2015, 59, 4260-4271.	3.2	30
168	Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial. Clinical Infectious Diseases, 2018, 67, 1364-1372.	5.8	30
169	Decreased bioefficacy of long-lasting insecticidal nets and the resurgence of malaria in Papua New Guinea. Nature Communications, 2020, 11, 3646.	12.8	30
170	Forest malaria in Cambodia: the occupational and spatial clustering of Plasmodium vivax and Plasmodium falciparum infection risk in a cross-sectional survey in Mondulkiri province, Cambodia. Malaria Journal, 2020, 19, 413.	2.3	30
171	Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malaria Journal, 2009, 8, 158.	2.3	29
172	Use of Antibiotics within the IMCI Guidelines in Outpatient Settings in Papua New Guinean Children: An Observational and Effectiveness Study. PLoS ONE, 2014, 9, e90990.	2.5	29
173	Antibodies to the<i>Plasmodium falciparum</i>Proteins MSPDBL1 and MSPDBL2 Opsonize Merozoites, Inhibit Parasite Growth, and Predict Protection From Clinical Malaria. Journal of Infectious Diseases, 2015, 212, 406-415.	4.0	29
174	Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against<i>Plasmodium falciparum</i>Malaria in Children. Clinical Infectious Diseases, 2015, 61, 1244-1252.	5.8	29
175	Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses. Trends in Parasitology, 2017, 33, 260-263.	3.3	29
176	Antibody responses to Plasmodium vivax Duffy binding and Erythrocyte binding proteins predict risk of infection and are associated with protection from clinical Malaria. PLoS Neglected Tropical Diseases, 2019, 13, e0006987.	3.0	29
177	<i>Plasmodium vivax</i>spleen-dependent genes encode antigens associated with cytoadhesion and clinical protection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13056-13065.	7.1	29
178	Subacute Sclerosing Panencephalitis in Papua New Guinean Children: The Cost of Continuing Inadequate Measles Vaccine Coverage. PLoS Neglected Tropical Diseases, 2011, 5, e932.	3.0	28
179	Antibody Targets on the Surface of<i>Plasmodium falciparumâ€“</i>Infected Erythrocytes That Are Associated With Immunity to Severe Malaria in Young Children. Journal of Infectious Diseases, 2019, 219, 819-828.	4.0	28
180	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27

#	Article	IF	Citations
181	The top 1%: quantifying the unequal distribution of malaria in Brazil. Malaria Journal, 2021, 20, 87.	2.3	27
182	Increasingly inbred and fragmented populations of Plasmodium vivax associated with the eastward decline in malaria transmission across the Southwest Pacific. PLoS Neglected Tropical Diseases, 2018, 12, e0006146.	3.0	27
183	Comparison of an assumed versus measured leucocyte count in parasite density calculations in Papua New Guinean children with uncomplicated malaria. Malaria Journal, 2014, 13, 145.	2.3	26
184	The Incidence and Differential Seasonal Patterns of Plasmodium vivax Primary Infections and Relapses in a Cohort of Children in Papua New Guinea. PLoS Neglected Tropical Diseases, 2016, 10, e0004582.	3.0	26
185	Malaria case management in Papua New Guinea following the introduction of a revised treatment protocol. Malaria Journal, 2013, 12, 433.	2.3	25
186	Accuracy of an HRP-2/panLDH rapid diagnostic test to detect peripheral and placental Plasmodium falciparum infection in Papua New Guinean women with anaemia or suspected malaria. Malaria Journal, 2015, 14, 412.	2.3	25
187	SNP barcodes provide higher resolution than microsatellite markers to measure Plasmodium vivax population genetics. Malaria Journal, 2020, 19, 375.	2.3	25
188	Minimal Association of Common Red Blood Cell Polymorphisms with Plasmodium falciparum Infection and Uncomplicated Malaria in Papua New Guinean School Children. American Journal of Tropical Medicine and Hygiene, 2010, 83, 828-833.	1.4	24
189	Pharmacokinetic Comparison of Two Piperaquine-Containing Artemisinin Combination Therapies in Papua New Guinean Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 3288-3297.	3.2	24
190	Multiplicity of Asymptomatic Plasmodium falciparum Infections and Risk of Clinical Malaria: A Systematic Review and Pooled Analysis of Individual Participant Data. Journal of Infectious Diseases, 2020, 221, 775-785.	4.0	24
191	Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles. PLoS Neglected Tropical Diseases, 2017, 11, e0005516.	3.0	24
192	Does Malaria Affect Placental Development? Evidence from In Vitro Models. PLoS ONE, 2013, 8, e55269.	2.5	24
193	Taking Sharper Pictures of Malaria with CAMERAs: Combined Antibodies to Measure Exposure Recency Assays. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1120-1127.	1.4	24
194	A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Malaria Journal, 2011, 10, 282.	2.3	23
195	High Genetic Diversity of Plasmodium vivax on the North Coast of Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2013, 89, 188-194.	1.4	23
196	Spatial Effects on the Multiplicity of Plasmodium falciparum Infections. PLoS ONE, 2016, 11, e0164054.	2.5	23
197	Antibodies to Intercellular Adhesion Molecule 1-Binding Plasmodium falciparum Erythrocyte Membrane Protein 1-DBLÎ² Are Biomarkers of Protective Immunity to Malaria in a Cohort of Young Children from Papua New Guinea. Infection and Immunity, 2018, 86, .	2.2	23
198	Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study. PLoS Medicine, 2021, 18, e1003535.	8.4	23

#	Article	IF	Citations
199	<i>In vitro</i>sensitivity of<i>Plasmodium falciparum</i>to conventional and novel antimalarial drugs in Papua New Guinea. Tropical Medicine and International Health, 2010, 15, 342-349.	2.3	22
200	Lumbar Puncture in Children from an Area of Malaria Endemicity Who Present with a Febrile Seizure. Clinical Infectious Diseases, 2010, 51, 534-540.	5.8	22
201	Chloroquine and Its Derivatives Exacerbate B19V-Associated Anemia by Promoting Viral Replication. PLoS Neglected Tropical Diseases, 2010, 4, e669.	3.0	22
202	Decreasing Malaria Prevalence and Its Potential Consequences for Immunity in Pregnant Women. Journal of Infectious Diseases, 2014, 210, 1444-1455.	4.0	22
203	Acquisition of Antibodies Against Endothelial Protein C Receptorâ€“Binding Domains of <i>Plasmodium falciparum</i> Erythrocyte Membrane Protein 1 in Children with Severe Malaria. Journal of Infectious Diseases, 2019, 219, 808-818.	4.0	22
204	MOLECULAR ANALYSIS OF PLASMODIUM FALCIPARUM FROM DRUG TREATMENT FAILURE PATIENTS IN PAPUA NEW GUINEA. American Journal of Tropical Medicine and Hygiene, 2004, 70, 251-255.	1.4	22
205	Molecular Assessment of <i>Plasmodium falciparum</i> Resistance to Antimalarial Drugs in Papua New Guinea Using an Extended Ligase Detection Reaction Fluorescent Microsphere Assay. Antimicrobial Agents and Chemotherapy, 2011, 55, 798-805.	3.2	21
206	Estimating the Burden of Malaria: The Need for Improved Surveillance. PLoS Medicine, 2011, 8, e1001144.	8.4	21
207	Epidemiology of malaria in the Papua New Guinean highlands. Tropical Medicine and International Health, 2012, 17, 1181-1191.	2.3	21
208	Pharmacokinetic Properties of Single-Dose Primaquine in Papua New Guinean Children: Feasibility of Abbreviated High-Dose Regimens for Radical Cure of Vivax Malaria. Antimicrobial Agents and Chemotherapy, 2014, 58, 432-439.	3.2	21
209	Knowledge, Attitudes, and Practices Concerning Malaria in Pregnancy: Results from a Qualitative Study in Madang, Papua New Guinea. PLoS ONE, 2015, 10, e0119077.	2.5	21
210	Patterns of protective associations differ for antibodies to <i>P. falciparum</i>â€‹infected erythrocytes and merozoites in immunity against malaria in children. European Journal of Immunology, 2017, 47, 2124-2136.	2.9	21
211	Single-cell RNA sequencing reveals developmental heterogeneity among Plasmodium berghei sporozoites. Scientific Reports, 2021, 11, 4127.	3.3	21
212	Factors associated with ultrasound-aided detection of suboptimal fetal growth in a malaria-endemic area in Papua New Guinea. BMC Pregnancy and Childbirth, 2015, 15, 83.	2.4	20
213	A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies. Cellular and Molecular Life Sciences, 2016, 73, 4141-4158.	5.4	20
214	Rapid Antigen Detection Tests for Malaria Diagnosis in Severely Ill Papua New Guinean Children: A Comparative Study Using Bayesian Latent Class Models. PLoS ONE, 2012, 7, e48701.	2.5	20
215	Microsatellite polymorphism within pfcrt provides evidence of continuing evolution of chloroquine-resistant alleles in Papua New Guinea. Malaria Journal, 2007, 6, 34.	2.3	19
216	Indifferent to disease: A qualitative investigation of the reasons why some Papua New Guineans who own mosquito nets choose not to use them. Social Science and Medicine, 2012, 75, 2283-2290.	3.8	19

#	Article	IF	Citations
217	A histopathologic study of fatal paediatric cerebral malaria caused by mixed Plasmodium falciparum/Plasmodium vivax infections. Malaria Journal, 2012, 11, 107.	2.3	19
218	Estimating the Numbers of Malaria Infections in Blood Samples Using High-Resolution Genotyping Data. PLoS ONE, 2012, 7, e42496.	2.5	19
219	Proinflammatory Responses and Higher IL-10 Production by T Cells Correlate with Protection against Malaria during Pregnancy and Delivery Outcomes. Journal of Immunology, 2015, 194, 3275-3285.	0.8	19
220	Determining effects of areca (betel) nut chewing in a prospective cohort of pregnant women in Madang Province, Papua New Guinea. BMC Pregnancy and Childbirth, 2015, 15, 177.	2.4	19
221	Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum. PLoS Neglected Tropical Diseases, 2017, 11, e0005753.	3.0	19
222	Nationwide genetic surveillance of Plasmodium vivax in Papua New Guinea reveals heterogeneous transmission dynamics and routes of migration amongst subdivided populations. Infection, Genetics and Evolution, 2018, 58, 83-95.	2.3	19
223	Differential impact of malaria control interventions on P. falciparum and P. vivax infections in young Papua New Guinean children. BMC Medicine, 2019, 17, 220.	5.5	19
224	Population Hemoglobin Mean and Anemia Prevalence in Papua New Guinea: New Metrics for Defining Malaria Endemicity?. PLoS ONE, 2010, 5, e9375.	2.5	18
225	Pyrethroid Susceptibility in Natural Populations of the Anopheles punctulatus Group (Diptera:) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	18
226	Population genetic analysis of the Plasmodium falciparum 6-cys protein Pf38 in Papua New Guinea reveals domain-specific balancing selection. Malaria Journal, 2011, 10, 126.	2.3	18
227	Characterization of Treatment Failure in Efficacy Trials of Drugs against Plasmodium vivax by Genotyping Neutral and Drug Resistance-Associated Markers. Antimicrobial Agents and Chemotherapy, 2011, 55, 4479-4481.	3.2	18
228	Costâ€“effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization, 2011, 89, 211-220.	3.3	18
229	Reference Intervals for Common Laboratory Tests in Melanesian Children. American Journal of Tropical Medicine and Hygiene, 2011, 85, 50-54.	1.4	18
230	Tolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age. Antimicrobial Agents and Chemotherapy, 2012, 56, 2146-2149.	3.2	18
231	Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea. Malaria Journal, 2015, 14, 399.	2.3	18
232	Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. British Journal of Clinical Pharmacology, 2016, 82, 199-212.	2.4	18
233	Antibodies to Plasmodium vivax reticulocyte binding protein 2b are associated with protection against P. vivax malaria in populations living in low malaria transmission regions of Brazil and Thailand. PLoS Neglected Tropical Diseases, 2019, 13, e0007596.	3.0	18
234	Plasmodium vivax VIR Proteins Are Targets of Naturally-Acquired Antibody and T Cell Immune Responses to Malaria in Pregnant Women. PLoS Neglected Tropical Diseases, 2016, 10, e0005009.	3.0	18

#	Article	IF	Citations
235	Treatment with Coartem (Artemether-Lumefantrine) in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2010, 82, 529-534.	1.4	17
236	Seeking treatment for symptomatic malaria in Papua New Guinea. Malaria Journal, 2010, 9, 268.	2.3	17
237	Research challenges and gaps in malaria knowledge in Papua New Guinea. Acta Tropica, 2012, 121, 274-280.	2.0	17
238	Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 4489-4496.	3.2	17
239	Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea. Malaria Journal, 2015, 14, 37.	2.3	17
240	A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens. BMC Medicine, 2016, 14, 144.	5.5	17
241	Heterogeneity in response to serological exposure markers of recent Plasmodium vivax infections in contrasting epidemiological contexts. PLoS Neglected Tropical Diseases, 2021, 15, e0009165.	3.0	17
242	P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission. PLoS ONE, 2017, 12, e0186577.	2.5	17
243	Prevention and treatment of malaria in pregnancy. Future Microbiology, 2010, 5, 1599-1613.	2.0	16
244	High Throughput Multiplex Assay for Species Identification of Papua New Guinea Malaria Vectors: Members of the Anopheles punctulatus (Diptera: Culicidae) Species Group. American Journal of Tropical Medicine and Hygiene, 2011, 84, 166-173.	1.4	16
245	Time trend of malaria in relation to climate variability in Papua New Guinea. Environmental Health and Toxicology, 2016, 31, e2016003.	1.8	16
246	Microscopic and submicroscopic Plasmodium falciparum infection, maternal anaemia and adverse pregnancy outcomes in Papua New Guinea: a cohort study. Malaria Journal, 2019, 18, 302.	2.3	16
247	Global Population Genomics of Two Subspecies of<i>Cryptosporidium hominis</i>during 500 Years of Evolution. Molecular Biology and Evolution, 2022, 39, .	8.9	16
248	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Research, 0, 7, 136.	1.8	16
249	Malaria â€“ a major health problem within an oil palm plantation around Popondetta, Papua New Guinea. Malaria Journal, 2009, 8, 56.	2.3	15
250	Multiplex Assay for Species Identification and Monitoring of Insecticide Resistance in Anopheles punctulatus Group Populations of Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2012, 86, 140-151.	1.4	15
251	Comparison of three methods for detection of gametocytes in Melanesian children treated for uncomplicated malaria. Malaria Journal, 2014, 13, 319.	2.3	15
252	Health Worker Compliance with a â€˜Test And Treatâ€™ Malaria Case Management Protocol in Papua New Guinea. PLoS ONE, 2016, 11, e0158780.	2.5	15

#	Article	IF	Citations
253	Azithromycinâ€containing intermittent preventive treatment in pregnancy affects gestational weight gain, an important predictor of birthweight in <scp>P</scp>apua <scp>N</scp>ew <scp>G</scp>uinea â€" an exploratory analysis. Maternal and Child Nutrition, 2016, 12, 699-712.	3.0	15
254	Effects of Plasmodium falciparum infection on umbilical artery resistance and intrafetal blood flow distribution: a Doppler ultrasound study from Papua New Guinea. Malaria Journal, 2017, 16, 35.	2.3	15
255	The treatment of non-malarial febrile illness in Papua New Guinea: findings from cross sectional and longitudinal studies of health worker practice. BMC Health Services Research, 2017, 17, 10.	2.2	15
256	IgG antibodies to synthetic GPI are biomarkers of immune-status to both Plasmodium falciparum and Plasmodium vivax malaria in young children. Malaria Journal, 2017, 16, 386.	2.3	15
257	Efficacy of artemetherâ€"lumefantrine and dihydroartemisininâ€"piperaquine for the treatment of uncomplicated malaria in Papua New Guinea. Malaria Journal, 2018, 17, 350.	2.3	15
258	Monitoring <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> using microsatellite markers indicates limited changes in population structure after substantial transmission decline in Papua New Guinea. Molecular Ecology, 2020, 29, 4525-4541.	3.9	15
259	Utility of ultra-sensitive qPCR to detect Plasmodium falciparum and Plasmodium vivax infections under different transmission intensities. Malaria Journal, 2020, 19, 319.	2.3	15
260	Surveillance of molecular markers of Plasmodium falciparum artemisinin resistance (kelch13) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 and Drug Resistance, 2021, 16, 188-193.	3.4	15
261	A comparison of non-magnetic and magnetic beads for measuring IgG antibodies against Plasmodium vivax antigens in a multiplexed bead-based assay using Luminex technology (Bio-Plex 200 or MAGPIX). PLoS ONE, 2020, 15, e0238010.	2.5	15
262	Epidemic malaria in the highlands of Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2005, 72, 554-60.	1.4	15
263	A review of the current state of malaria among pregnant women in Papua New Guinea. Papua and New Guinea Medical Journal, 2008, 51, 12-6.	1.0	15
264	Pharmacokinetic Properties of Conventional and Double-Dose Sulfadoxine-Pyrimethamine Given as Intermittent Preventive Treatment in Infancy. Antimicrobial Agents and Chemotherapy, 2011, 55, 1693-1700.	3.2	14
265	The economic cost to households of childhood malaria in Papua New Guinea: a focus on intra-country variation. Health Policy and Planning, 2012, 27, 339-347.	2.7	14
266	Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. International Journal of Antimicrobial Agents, 2017, 50, 542-551.	2.5	14
267	Global diversity and balancing selection of 23 leading Plasmodium falciparum candidate vaccine antigens. PLoS Computational Biology, 2022, 18, e1009801.	3.2	14
268	Meningeal Inflammation Increases Artemether Concentrations in Cerebrospinal Fluid in Papua New Guinean Children Treated with Intramuscular Artemether. Antimicrobial Agents and Chemotherapy, 2011, 55, 5027-5033.	3.2	13
269	Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens. BMC Microbiology, 2015, 15, 133.	3.3	13
270	High Efficacy of Primaquine Treatment for Plasmodium vivax in Western Thailand. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1086-1089.	1.4	13

#	Article	IF	Citations
271	Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection. Scientific Reports, 2019, 9, 2260.	3.3	13
272	Repeated mosquito net distributions, improved treatment, and trends in malaria cases in sentinel health facilities in Papua New Guinea. Malaria Journal, 2019, 18, 364.	2.3	13
273	Comparative genomics revealed adaptive admixture in Cryptosporidium hominis in Africa. Microbial Genomics, 2021, 7, .	2.0	13
274	Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2004, 70, 251-5.	1.4	13
275	Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection. Vaccine, 2009, 27, 5633-5643.	3.8	12
276	Malaria case management in Papua New Guinea prior to the introduction of a revised treatment protocol. Malaria Journal, 2012, 11, 157.	2.3	12
277	Effectiveness of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax and P. falciparum Malaria in Young Children in Papua New Guinea. Clinical Infectious Diseases, 2013, 56, 1413-1420.	5.8	12
278	Pharmacokinetics of Piperaquine Transfer into the Breast Milk of Melanesian Mothers. Antimicrobial Agents and Chemotherapy, 2015, 59, 4272-4278.	3.2	12
279	The epidemiology of Plasmodium falciparum and Plasmodium vivax in East Sepik Province, Papua New Guinea, pre- and post-implementation of national malaria control efforts. Malaria Journal, 2020, 19, 198.	2.3	12
280	Investigating differences in village-level heterogeneity of malaria infection and household risk factors in Papua New Guinea. Scientific Reports, 2021, 11, 16540.	3.3	12
281	Identification of the asymptomatic Plasmodium falciparum and Plasmodium vivax gametocyte reservoir under different transmission intensities. PLoS Neglected Tropical Diseases, 2021, 15, e0009672.	3.0	12
282	Microsatellite Genotyping of Plasmodium vivax Isolates from Pregnant Women in Four Malaria Endemic Countries. PLoS ONE, 2016, 11, e0152447.	2.5	12
283	Dynamics of Asymptomatic Plasmodium vivax Infections and Duffy Binding Protein Polymorphisms in Relation to Parasitemia Levels in Papua New Guinean Children. American Journal of Tropical Medicine and Hygiene, 2007, 77, 955-962.	1.4	12
284	Serology for Plasmodium vivax surveillance: A novel approach to accelerate towards elimination. Parasitology International, 2022, 87, 102492.	1.3	12
285	Investigation of reproductive toxicity of piperaquine in mice. Reproductive Toxicology, 2010, 29, 206-213.	2.9	11
286	Robert Koch redux: malaria immunology in Papua New Guinea. Parasite Immunology, 2010, 32, 623-632.	1.5	11
287	Increasing Chloramphenicol Resistance in Streptococcus pneumoniae Isolates from Papua New Guinean Children with Acute Bacterial Meningitis. Antimicrobial Agents and Chemotherapy, 2011, 55, 4454-4456.	3.2	11
288	Lack of associations of Î±-thalassemia with the risk of Plasmodium falciparum and Plasmodium vivax infection and disease in a cohort of children aged 3â€"21 months from Papua New Guinea. International Journal for Parasitology, 2012, 42, 1107-1113.	3.1	11

#	Article	IF	Citations
289	The exit interview as a proxy measure of malaria case management practice: sensitivity and specificity relative to direct observation. BMC Health Services Research, 2014, 14, 628.	2.2	11
290	Different Regions of<i>Plasmodium falciparum</i>Erythrocyte-Binding Antigen 175 Induce Antibody Responses to Infection of Varied Efficacy. Journal of Infectious Diseases, 2016, 214, 96-104.	4.0	11
291	Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein in Pregnant Women Are Associated with Higher Birth Weight in a Multicenter Study. Frontiers in Immunology, 2017, 8, 163.	4.8	11
292	A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
293	PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus. Communications Biology, 2022, 5, 168.	4.4	11
294	Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine + Sulfadoxine- Pyrimethamine for Malaria: A Randomized Trial. PLOS Clinical Trials, 2006, 1, e38.	3.5	10
295	Community response to intermittent preventive treatment of malaria in infants (IPTi) in Papua New Guinea. Malaria Journal, 2010, 9, 369.	2.3	10
296	Risk factors for Plasmodium falciparum and Plasmodium vivax gametocyte carriage in Papua New Guinean children with uncomplicated malaria. Acta Tropica, 2016, 160, 1-8.	2.0	10
297	Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study. Malaria Journal, 2021, 20, 177.	2.3	10
298	Reduced risk of placental parasitemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women. BMC Medicine, 2021, 19, 201.	5.5	10
299	CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 310-9.	0.4	10
300	Malaria control in Papua New Guinea results in complex epidemiological changes. Papua and New Guinea Medical Journal, 2005, 48, 151-7.	1.0	10
301	Dynamics of asymptomatic Plasmodium vivax infections and Duffy binding protein polymorphisms in relation to parasitemia levels in Papua New Guinean children. American Journal of Tropical Medicine and Hygiene, 2007, 77, 955-62.	1.4	10
302	Developing sero-diagnostic tests to facilitate Plasmodium vivax Serological Test-and-Treat approaches: modeling the balance between public health impact and overtreatment. BMC Medicine, 2022, 20, 98.	5.5	10
303	Toxicology and pharmacokinetics of piperaquine in mice. Toxicology, 2008, 249, 55-61.	4.2	9
304	Heterogeneous distribution of Plasmodium falciparum drug resistance haplotypes in subsets of the host population. Malaria Journal, 2008, 7, 78.	2.3	9
305	Predictors of Acute Bacterial Meningitis in Children from a Malaria-Endemic Area of Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2012, 86, 240-245.	1.4	9
306	Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission. Malaria Journal, 2015, 14, 215.	2.3	9

#	Article	IF	Citations
307	Impact of Intermittent Preventive Treatment in Pregnancy with Azithromycin-Containing Regimens on Maternal Nasopharyngeal Carriage and Antibiotic Sensitivity of Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus: a Cross-Sectional Survey at Delivery. Journal of Clinical Microbiology, 2015, 53, 1317-1323.	3.9	9
308	Use of anthropophilic culicid-based xenosurveillance as a proxy for Plasmodium vivax malaria burden and transmission hotspots identification. PLoS Neglected Tropical Diseases, 2018, 12, e0006909.	3.0	9
309	Molecular epidemiology of residual Plasmodium vivax transmission in a paediatric cohort in Solomon Islands. Malaria Journal, 2019, 18, 106.	2.3	9
310	Application of 23 Novel Serological Markers for Identifying Recent Exposure to Plasmodium vivax Parasites in an Endemic Population of Western Thailand. Frontiers in Microbiology, 2021, 12, 643501.	3.5	9
311	Seroprevalence of Antibodies to Parvovirus B19 among Children in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2007, 77, 354-357.	1.4	9
312	Vaccines against malaria: Perspectives from Papua, New Guinea. Hum Vaccin, 2010, 6, 17-20.	2.4	8
313	Retrospective study on the usefulness of pulse oximetry for the identification of young children with severe illnesses and severe pneumonia in a rural outpatient clinic of Papua New Guinea. PLoS ONE, 2019, 14, e0213937.	2.5	8
314	Transcriptional Memory-Like Imprints and Enhanced Functional Activity in Î³Î´ T Cells Following Resolution of Malaria Infection. Frontiers in Immunology, 2020, 11, 582358.	4.8	8
315	Cytokine signatures ofÂPlasmodium vivax infection during pregnancy and delivery outcomes. PLoS Neglected Tropical Diseases, 2020, 14, e0008155.	3.0	8
316	IgG Antibody Responses Are Preferential Compared With IgM for Use as Serological Markers for Detecting Recent Exposure to <i>Plasmodium vivax</i> Infection. Open Forum Infectious Diseases, 2021, 8, ofab228.	0.9	8
317	Plasmodium falciparum and Plasmodium vivax Genotypes and Efficacy of Intermittent Preventive Treatment in Papua New Guinea. Antimicrobial Agents and Chemotherapy, 2014, 58, 6958-6961.	3.2	7
318	Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western Pacific. BMJ Open, 2016, 6, e012697.	1.9	7
319	Studying Land Cover Changes in a Malaria-Endemic Cambodian District: Considerations and Constraints. Remote Sensing, 2020, 12, 2972.	4.0	7
320	The epidemiology of malaria in the Papua New Guinea highlands: 2. Eastern Highlands Province. Papua and New Guinea Medical Journal, 2003, 46, 166-79.	1.0	7
321	The epidemiology of malaria in the Papua New Guinea highlands: 3. Simbu Province. Papua and New Guinea Medical Journal, 2004, 47, 159-73.	1.0	7
322	Naturally acquired antibody kinetics against Plasmodium vivax antigens in people from a low malaria transmission region in western Thailand. BMC Medicine, 2022, 20, 89.	5.5	7
323	Viral pathogens in children hospitalized with features of central nervous system infection in a malaria-endemic region of Papua New Guinea. BMC Infectious Diseases, 2014, 14, 630.	2.9	6
324	Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b. Nature Communications, 2021, 12, 1538.	12.8	6

#	Article	IF	Citations
325	Indigenous Plasmodium malariae Infection in an Endemic Population at the Thaiâ€"Myanmar Border. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1164-1169.	1.4	6
326	Complex patterns of malaria epidemiology in the highlands region of Papua New Guinea. Papua and New Guinea Medical Journal, 2002, 45, 200-5.	1.0	6
327	Malaria transmission structure in the Peruvian Amazon through antibody signatures to Plasmodium vivax. PLoS Neglected Tropical Diseases, 2022, 16, e0010415.	3.0	6
328	Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P.Âknowlesi. Cell Reports Medicine, 2022, 3, 100662.	6.5	6
329	Mechanisms Underlying Early Interferonâ€Î³ Production in HumanPlasmodium falciparumMalaria. Clinical Infectious Diseases, 2009, 48, 1482-1483.	5.8	5
330	Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery. PLoS Medicine, 2011, 8, e1000410.	8.4	5
331	Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	5
332	Hemoglobin Levels and the Risk of Malaria in Papua New Guinean Infants: A Nested Cohort Study. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1770-1776.	1.4	5
333	Peripheral Blood Mononuclear Cells Derived from Grand Multigravidae Display a Distinct Cytokine Profile in Response to P. falciparum Infected Erythrocytes. PLoS ONE, 2014, 9, e86160.	2.5	4
334	Fetal Size in a Rural Melanesian Population with Minimal Risk Factors for Growth Restriction: An Observational Ultrasound Study from Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2015, 92, 178-186.	1.4	4
335	SARS-CoV-2 Multi-Antigen Serology Assay. Methods and Protocols, 2021, 4, 72.	2.0	4
336	Seroprevalence of antibodies to parvovirus B19 among children in Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 2007, 77, 354-7.	1.4	4
337	The epidemiology of malaria in the Papua New Guinea highlands: 4. Enga Province. Papua and New Guinea Medical Journal, 2006, 49, 115-25.	1.0	4
338	The epidemiology of malaria in the Papua New Guinea highlands: 5. Aseki, Menyamya and Wau-Bulolo, Morobe Province. Papua and New Guinea Medical Journal, 2007, 50, 111-22.	1.0	4
339	Adoption and Hospital Admission in Port Moresby, Papua New Guinea. Journal of Tropical Pediatrics, 2002, 48, 264-269.	1.5	3
340	Vivax malaria: more severe and more resistant. Therapy: Open Access in Clinical Medicine, 2010, 7, 39-48.	0.2	3
341	Limited Degradation of the Plasmodium falciparum Gametocyte Marker pfs25 mRNA Exposed to Tropical Temperatures: Considerations for Malaria Transmission Field Studies. American Journal of Tropical Medicine and Hygiene, 2016, 94, 886-889.	1.4	3
342	Identifying the risks for human transmission of Plasmodium knowlesi. Lancet Planetary Health, The, 2017, 1, e83-e85.	11.4	3

#	Article	IF	Citations
343	Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial. PLoS ONE, 2019, 14, e0210789.	2.5	3
344	High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women. Frontiers in Immunology, 2021, 12, 644563.	4.8	3
345	Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria. PLoS ONE, 2017, 12, e0179863.	2.5	3
346	The epidemiology of malaria in the Papua New Guinea highlands: 1. Western Highlands Province. Papua and New Guinea Medical Journal, 2003, 46, 16-31.	1.0	3
347	Prevalence and force of Plasmodium vivax blood-stage infection and associated clinical malaria burden in the Brazilian Amazon. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	1.6	3
348	Does test-based prescription of evidence-based treatment for malaria improve treatment seeking and satisfaction? Findings of repeated cross-sectional surveys in Papua New Guinea. BMJ Global Health, 2018, 3, e000915.	4.7	2
349	The impact of the scale-up of malaria rapid diagnostic tests on the routine clinical diagnosis procedures for febrile illness: a series of repeated cross-sectional studies in Papua New Guinea. Malaria Journal, 2018, 17, 202.	2.3	2
350	Sensitive detection of Plasmodium vivax malaria by the rotating-crystal magneto-optical method in Thailand. Scientific Reports, 2021, 11, 18547.	3.3	2
351	Joint Modeling of Mixed Plasmodium Species Infections Using a Bivariate Poisson Lognormal Model. American Journal of Tropical Medicine and Hygiene, 2018, 98, 71-76.	1.4	2
352	The epidemiology of malaria in the Papua New Guinea highlands: 6. Simbai and Bundi, Madang Province. Papua and New Guinea Medical Journal, 2007, 50, 123-33.	1.0	2
353	The epidemiology of malaria in the Papua New Guinea highlands: 7. Southern Highlands Province. Papua and New Guinea Medical Journal, 2011, 54, 35-47.	1.0	2
354	Comparison of total immunoglobulin G antibody responses to different protein fragments of Plasmodium vivax Reticulocyte binding protein 2b. Malaria Journal, 2022, 21, 71.	2.3	2
355	Mobility evaluation by GPS tracking in a rural, low-income population in Cambodia. PLoS ONE, 2022, 17, e0266460.	2.5	1
356	Editorial on the special issue on Plasmodium vivax: Current situation and challenges towards elimination. Parasitology International, 2022, 89, 102594.	1.3	1
357	Plasmodium vivax in Oceania. Neglected Tropical Diseases, 2016, , 153-176.	0.4	0
358	Missing malaria? Potential obstacles to diagnosis and hypnozoite eradication. Medical Journal of Australia, 2015, 202, 360-360.	1.7	0
359	Protective Immunity Against Severe Malaria is Associated with a Repertoire of Antibodies to Conserved PfEMP1 Variants. SSRN Electronic Journal, 0, , .	0.4	0
360	Title is missing!. , 2020, 17, e1003393.		0

#	Article	IF	Citations
361	Title is missing!. , 2020, 17, e1003393.		0
362	Title is missing!. , 2020, 17, e1003393.		0
363	Title is missing!. , 2020, 17, e1003393.		0
364	Title is missing!. , 2020, 17, e1003393.		0
365	Title is missing!. , 2020, 15, e0238010.		0
366	Title is missing!. , 2020, 15, e0238010.		0
367	Title is missing!. , 2020, 15, e0238010.		0
368	Title is missing!. , 2020, 15, e0238010.		0
369	Title is missing!. , 2020, 15, e0238010.		0
370	Title is missing!. , 2020, 15, e0238010.		0